AI Summary & Key Takeaways
AI InsightThe groups were compared in terms of pre-treatment general features, post-treatment biochemical recurrence, metastasis, disease-free survival and overall survival.
📌 3 Key Takeaways
Abstract
Introduction: We aimed to compare the outcomes of high risk prostate cancer treatments with radical prostatectomy (RP) or radiotherapy (RT) and androgen deprivation therapy (ADT). Methods: 83 patients who were treated with RT and ADT or radical prostatectomy for high risk prostate cancer between April 2010 and May 2018 and whose data were retrospectively analyzed were included in our study. While 40 patients received RT and ADT combination therapy, 43 patients received RP. The groups were compared in terms of pre-treatment general features, post-treatment biochemical recurrence, metastasis, disease-free survival and overall survival. Results: The mean age of the patients was 64.05 (50-74) years in the surgical group and 69.35 (49-79) years in the RT group. The mean prostate-specific antigen baseline value was 22.79 (3-93) ng/ml in the surgical group and 40.60 (3-201) ng/ml in the RT group. Biochemical recurrence was observed in 15 (34.8%) patients in the surgical group and 2 (5%) patients in the RT group. Disease-free survival time was 31.12 (12-68) months in the surgical group and 41.4 (16-88) months in the RT group. Discussion and Conclusion: Our study results revealed that RT and ADT application has more advantageous oncological results in the treatment of high-risk prostate cancer, as in many studies.